Transgenomic takes up SpectruMedix challenge

Transgenomic will provide Spectrumedix instrument service and consumables support in the United States and other areas as well as continue the offering to its Spectrumedix customers in Europe

Transgenomic, the exclusive Spectrumedix systems European distributor since 2003, and Spectrumedix customers were affected by the SpectruMedix decision to discontinue operations after 9 March 2007.

Spectrumedix systems are high-throughput capillary electrophoresis (CE) instruments ideal for many applications including comparative genome scanning, SNP genotyping, heterozygote identification, fragment sizing, PCR quality testing, and custom assay development.

Transgenomic also announced that it has acquired certain assets from the SpectruMedix court-appointed receiver and a license from the gel patent holder necessary to manufacture consumables for Spectrumedix systems.

The financial terms of these transactions were not disclosed.

Transgenomic's president and chief executive officer, Craig Tuttle, stated: "We have obviously been concerned about the ongoing issue of consumables and spare parts supply to our European Spectrumedix systems customers.

"We are pleased to announce this series of transactions which clarifies this situation for Transgenomic and its European customers subject to the limitations of no longer being supported by Spectrumedix itself.

"Additionally, we intend to service and support other Spectrumedix customers as well, subject again to the same limitations.".

Back to top